Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New agents to combat the plague

11.01.2012
The plague is believed to have been eradicated in Europe. But it continues to reappear in other parts of the world, such as Madagascar, the Congo, and Peru. Since the pathogens are becoming resistant to the usual antibiotics, new agents are urgently needed. Progress has now been made in this area.

A wonderful breakthrough for scientists from the universities of Würzburg and Stony Brook (USA): they have shed light on the binding and action mechanisms of two new inhibitors that attack the plague pathogen, the bacterium Yersinia pestis. In the current issue of the journal “Structure” they present both substances, which belong to the pyridone group.


A newly developed inhibitor (magenta) from the pyridone group binds to a vital enzyme of the plague pathogen. The cofactor of the enzyme, NADH, which contributes significantly to the effect of the inhibitor, is shown in blue.
Image: Maria Hirschbeck

The new inhibitors attach themselves to the bacterial enzyme FabV and impede it in its work. This enzyme performs the final step in the production of bacterial fatty acids. If it is blocked, the plague pathogen dies. This is because without fatty acids it cannot maintain its protective shell, the cell membrane.

“But the two substances do not inhibit the enzyme well enough yet,” says Professor Caroline Kisker of the Rudolf Virchow Center at the University of Würzburg. For that reason, these new inhibitors and their interactions with the enzyme now need to be analyzed further and improved.

Steps to improve the inhibitors

Structural biologist Kisker, her doctoral student Maria Hirschbeck, and postdoctoral fellow Jochen Kuper are collaborating on this with Würzburg chemists and pharmacists Professor Christoph Sotriffer and Steffen Wagner as well as with Peter Tonge of Stony Brook University. In their laboratories, these scientists are working not with pathogens of the plague, but with the isolated enzyme. They are crystallizing it as a compound with the inhibitors, rendering it into a state in which they can analyze how the inhibitors attach themselves to the enzyme right down to the molecular level.

Christoph Sotriffer, an expert in computer modeling of molecules, and his staff then examine the crystal structures and propose changes to the inhibitors that might make these even more effective. Finally, the modified inhibitors are synthesized and re-tested: test-tube experiments reveal whether they really are further weakening this enzyme that is so vital to the plague pathogen.

“This cycle will generally have to be repeated several times until, ideally, we end up with a highly active inhibitor,” says Caroline Kisker. However, whether the inhibitor will then also be suitable as medication is far from certain. Numerous other tests will be needed to determine that.

This research is contained within the Würzburg Collaborative Research Center 630 (Recognition, Preparation, and Functional Analysis of Agents against Infectious Diseases). The German Research Foundation (DFG) is funding the work.

Progression of an infection with the plague pathogen

The pathogens of the plague tend to live in rodents, particularly rats. They can be transferred to humans through bites from infected rat fleas. After one to seven days, the sufferer develops a high fever and shivering, among other things. These symptoms are joined by painful buboes, swellings of the lymph nodes that appear like lumps on the skin. In rare cases, the lumps rupture outwards, according to the Robert Koch Institute.

As the disease progresses, the pathogens may also attack internal organs, especially the lungs. It is then common for the sufferer to cough up blood. At this stage, the pathogens can also be transmitted from human to human in droplets of coughed-up fluid. Without treatment with antibiotics, this pneumonic plague, as it is known, almost always ends in death. With bubonic plague, on the other hand, there is a 50 percent chance of survival even without treatment. Generally speaking, if the plague is detected early, it can be treated successfully with antibiotics – provided that these are still effective.

Resistant plague pathogens discovered

In 2010, scientists from the Pasteur Institute in Paris found two plague pathogen strains that no longer respond to antibiotics. Both came from Madagascar. This island south-east of Africa is a hotspot for global outbreaks of the plague: in 2010, there were 313 recognized cases of the disease here, according to statistics from the World Health Organization (WHO). The second-highest incidence of infection was found in the Congo (152), followed by Peru with 27 cases.

“Structure of the Yersinia pestis FabV Enoyl-ACP Reductase and its Interaction with two 2-Pyridone Inhibitors”, Maria W. Hirschbeck, Jochen Kuper, Hao Lu, Nina Liu, Carla Neckles, Sonam Shah, Steffen Wagner, Christoph A. Sotriffer, Peter J. Tonge, and Caroline Kisker. Structure, Vol. 20, Issue 1, 89-100, 11 January 2012, DOI 10.1016/j.str.2011.07.019

Contact

Prof. Dr. Caroline Kisker, Institute of Structural Biology, Rudolf Virchow Center / DFG Research Center for Experimental Biomedicine, T +49 (0)931 31-80381, caroline.kisker@virchow.uni-wuerzburg.de

Robert Emmerich | Julius-Maximilians-Universität W
Further information:
http://www.virchow.uni-wuerzburg.de

More articles from Life Sciences:

nachricht Cryo-electron microscopy achieves unprecedented resolution using new computational methods
24.03.2017 | DOE/Lawrence Berkeley National Laboratory

nachricht How cheetahs stay fit and healthy
24.03.2017 | Forschungsverbund Berlin e.V.

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Giant Magnetic Fields in the Universe

Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.

The results will be published on March 22 in the journal „Astronomy & Astrophysics“.

Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...

Im Focus: Tracing down linear ubiquitination

Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.

Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...

Im Focus: Perovskite edges can be tuned for optoelectronic performance

Layered 2D material improves efficiency for solar cells and LEDs

In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...

Im Focus: Polymer-coated silicon nanosheets as alternative to graphene: A perfect team for nanoelectronics

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.

Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...

Im Focus: Researchers Imitate Molecular Crowding in Cells

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.

Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

International Land Use Symposium ILUS 2017: Call for Abstracts and Registration open

20.03.2017 | Event News

CONNECT 2017: International congress on connective tissue

14.03.2017 | Event News

ICTM Conference: Turbine Construction between Big Data and Additive Manufacturing

07.03.2017 | Event News

 
Latest News

Argon is not the 'dope' for metallic hydrogen

24.03.2017 | Materials Sciences

Astronomers find unexpected, dust-obscured star formation in distant galaxy

24.03.2017 | Physics and Astronomy

Gravitational wave kicks monster black hole out of galactic core

24.03.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>